![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, November 01, 2023 4:23:04 AM
Source: Dow Jones News
By Ben Otto
British drugmaker AstraZeneca plans to invest $245 million in a deal with biotechnology company Cellectis to develop next-generation therapeutics in oncology, immunology and rare diseases.
AstraZeneca said Wednesday that it will initially make a $105 million payment to Paris-based Cellectis in the fourth quarter, comprising an $80 million equity investment, for a 22% stake in the company, and $25 million in cash.
AstraZeneca plans to make a further $140 million equity investment, subject to regulatory and other approvals, with a closing in early 2024, taking its total stake in Cellectis to 44%.
AstraZeneca said it plans to leverage Cellectis's gene-editing technologies and manufacturing capabilities to design novel cell and gene therapy products.
Cellectis will be eligible to receive an investigational new drug option fee and various milestone payments ranging from $70 million to up to $220 million for each of 10 candidate products, plus tiered royalties, AstraZeneca said.
AstraZeneca will retain an option for an exclusive license for the products developed under the research collaboration agreement.
Recent CLLS News
- Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024 • GlobeNewswire Inc. • 06/28/2024 08:30:00 PM
- Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing • GlobeNewswire Inc. • 06/20/2024 08:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/12/2024 08:35:05 PM
- Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications • GlobeNewswire Inc. • 06/12/2024 08:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/04/2024 08:41:02 PM
- Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia • GlobeNewswire Inc. • 06/04/2024 08:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/29/2024 08:35:05 PM
- Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024 • GlobeNewswire Inc. • 05/29/2024 08:30:00 PM
- Cellectis Reports Financial Results for First Quarter 2024 • GlobeNewswire Inc. • 05/28/2024 08:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/28/2024 10:00:10 AM
- Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024 • GlobeNewswire Inc. • 05/27/2024 08:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/24/2024 08:06:01 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/06/2024 10:00:09 AM
- Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca • GlobeNewswire Inc. • 05/06/2024 06:00:00 AM
- Cellectis Appoints Arthur Stril as Interim Chief Financial Officer • GlobeNewswire Inc. • 05/02/2024 08:30:00 PM
- Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023 • GlobeNewswire Inc. • 04/29/2024 08:46:43 PM
- Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs • GlobeNewswire Inc. • 04/22/2024 08:30:00 PM
- Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs • GlobeNewswire Inc. • 04/10/2024 08:30:00 PM
- Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting • GlobeNewswire Inc. • 04/08/2024 08:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/16/2024 09:45:04 PM
- Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB) • GlobeNewswire Inc. • 01/16/2024 09:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/22/2023 09:35:09 PM
- Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023 • GlobeNewswire Inc. • 12/22/2023 09:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/22/2023 09:01:49 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/05/2023 09:01:57 PM
FEATURED BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • Jul 2, 2024 7:19 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM